AVITA MEDICAL INC (AVH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

AVH - AVITA MEDICAL INC

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.34
Index:

Avita Medical is developing and marketing a range of regenerative skin products. It is headquartered in California and listed on the ASX and NASDAQ.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.61

15 May
2024

-0.170

OPEN

$2.67

-6.12%

HIGH

$2.67

479,339

LOW

$2.61

TARGET
$5.10 95.4% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
AVH: 1
Title FY24
Forecast		 FY25
Forecast
EPS (cps) - 131.8 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-42.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx75.5 M
Book Value Per Share xxxxxxxxxxxxxxx56.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-57.3 M
Net Profit Margin xxxxxxxxxxxxxxx-70.56 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-54.16 %
Return on Invested Capital xxxxxxxxxxxxxxx-41.30 %
Return on Assets xxxxxxxxxxxxxxx-34.56 %
Return on Equity xxxxxxxxxxxxxxx-54.16 %
Return on Total Capital xxxxxxxxxxxxxxx-142.42 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-59.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx61 M
Total Debt xxxxxxxxxxxxxxx62 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx131 M
Price To Book Value xxxxxxxxxxxxxxx7.66

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx2.2 M
Capex % of Sales xxxxxxxxxxxxxxx2.89 %
Cost of Goods Sold xxxxxxxxxxxxxxx12 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx249 M
Research & Development xxxxxxxxxxxxxxx31 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

15/04/2024

3

Downgrade to Speculative Hold from Speculative Buy

$3.50

34.10%

Bell Potter notes a worrying and unexplained decline in utilisation rates in the core burns market for Avita Medical after management downgraded 1Q revenues to between US$11.1-11.3m from the mid point of the prior range of US$15.2m.

While management has maintained its full year guidance, albeit now at the low end of the guidance range, the analysts don't share this optimism. The rating is downgraded to Speculative Hold from Speculative Buy and the target slashed to $3.50 from $6.85.

The broker speculates softness in the burns market may be due to overstocking of the channel in the December quarter and/or budget restraints within US hospitals in favour of cheaper treatment alternatives.

Also, burns adoption could have been flat with negligible uptake in full-thickness skin defects (FTSD), suggest the analysts.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -235.18 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -4.57 cents.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

AVH STOCK CHART

FNArena News on AVH

1
Weekly Ratings, Targets, Forecast Changes – 19-04-24

Apr 22 2024 - Weekly Reports
2
In Case You Missed It – BC Extra Upgrades & Downgrades – 19-04-24

Apr 19 2024 - Weekly Reports
3
Australian Broker Call *Extra* Edition – Apr 18, 2024

Apr 18 2024 - Daily Market Reports
4
Weekly Ratings, Targets, Forecast Changes – 12-04-24

Apr 15 2024 - Weekly Reports
5
Rudi’s View: Investor Worries, Gold, Westpac, and Conviction Buys

Apr 03 2024 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Invion

May 13 2024 - Small Caps
2
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps
3
The Power Of New Weight-Loss Drugs

Apr 03 2024 - International
4
Dr Boreham’s Crucible: Neuren Pharmaceuticals

Mar 11 2024 - Small Caps
5
Spotlight On ASX-Listed Cannabis Companies

Jan 31 2024 - Small Caps
6
Transformational Trial Results For Neuren Pharmaceuticals

Dec 20 2023 - Small Caps
7
Dr Boreham’s Crucible: Imugene

Dec 11 2023 - Small Caps
8
Dr Boreham’s Crucible: PYC Therapeutics

Nov 22 2023 - Small Caps
9
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023 - Small Caps
10
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps